GlassScriptPhysician profile
Keyona J Burden
NPI 1831715218
$3,784.60
in general payments reported to CMS, 2019-2025
28 companies · $14.04 in 2025
The $14.04 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,701 · 2022: $757 · 2023: $245 · 2024: $68.02 · 2025: $14.04.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $327.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $326.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $496.77 | 2021-2024 | |
| Novo Nordisk INC | $404.59 | 2021-2022 | |
| Lilly USA, LLC | $372.93 | 2021-2022 | |
| Medtronic, INC. | $351.42 | 2021-2022 | |
| Dexcom, INC. | $261.12 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $244.97 | 2021-2022 | |
| Amgen INC. | $223.16 | 2021-2022 | |
| Amarin Pharma, INC. | $211.32 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $175.27 | 2021-2022 | |
| Recordati_rare_diseases_inc. | $166.94 | 2021-2022 | |
| Galderma Laboratories, L.P. | $159.83 | 2022-2025 | Dysport |
| Allergan, INC. | $128.43 | 2022 | |
| Sanofi-Aventis U.S. LLC | $83.08 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $80.02 | 2021-2022 | |
| Currax Pharmaceuticals LLC | $69.88 | 2021-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amryt Pharma Holdings LTD | $53.52 | 2021-2022 | |
| Clarus Therapeutics INC. | $53.30 | 2021 | |
| Alexion Pharmaceuticals, INC. | $32.29 | 2021 | |
| Insulet Corporation | $30.99 | 2021-2022 | |
| Corcept Therapeutics | $29.68 | 2021-2022 | |
| Amneal Pharmaceuticals LLC | $28.35 | 2021 | |
| Radius Health, INC. | $26.17 | 2021 | |
| Merck Sharp & Dohme LLC | $25.53 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $19.97 | 2021 | |
| Novartis Pharmaceuticals Corporation | $14.99 | 2021 | |
| Eusa Pharma (US) LLC | $13.81 | 2022 | |
| Antares Pharma, INC. | $13.15 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keyona Burden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.